Drug Details
| General Information of the Drug (ID: DR1119) | ||||
|---|---|---|---|---|
| Name |
Nimesulide
|
|||
| Synonyms |
nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Aulin; Flogovital; Sulidene; Nimed; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; R-805; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; R 805; Nisulid; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; MFCD00079470; NCGC00015725-02; SMR000058484; CAS-51803-78-2; DSSTox_CID_17250; DSSTox_RID_79316; DSSTox_GSID_37250; Antifloxil; Nimesulida; Nimesulidum; Guaxan; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; NIM; Nimesulide [INN:BAN]; SR-01000000218; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; Aldoron; Nimedex; Orthobid; CCRIS 8225; Nise Gel; Nimesulide,(S); Prestwick_618; Spectrum_001577; Nimesulide (JAN/INN); Opera_ID_1247; Prestwick0_000194; Prestwick1_000194; Prestwick2_000194; Prestwick3_000194; Spectrum2_001541; Spectrum3_001576; Spectrum4_000178; Spectrum5_000964; Lopac-N-1016; N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide; Lopac0_000855; SCHEMBL24882; BSPBio_000147; BSPBio_001103; BSPBio_003112; KBioGR_000443; KBioGR_000695; KBioSS_000443; KBioSS_002057; MLS001148268; DivK1c_000693; SPECTRUM1503231; SPBio_001382; SPBio_002068; N-(4-nitro-2-phenoxyphenyl); BPBio1_000163; GTPL7401; NIM-03; DTXSID3037250; BCBcMAP01_000034; HMS502C15; KBio1_000693; KBio2_000443; KBio2_002057; KBio2_003011; KBio2_004625; KBio2_005579; KBio2_007193; KBio3_000825; KBio3_000826; KBio3_002612; NINDS_000693; Bio2_000382; Bio2_000862; HMS1362G05; HMS1568H09; HMS1792G05; HMS1922K17; HMS1990G05; HMS2089B14; HMS2095H09; HMS2234K19; HMS3262L11; HMS3269G17; HMS3371J19; HMS3403G05; HMS3414P09; HMS3649A04; HMS3655D13; HMS3678P07; HMS3712H09; HMS3884C22; Pharmakon1600-01503231; BCP10076; HY-B0363; ZINC4617749; Tox21_110207; Tox21_301850; Tox21_500855; BDBM50056999; CCG-39319; CN0038; EI-287; NSC758412; s2040; STL018679; AKOS015897356; Tox21_110207_1; AC-4524; DB04743; KS-1277; LP00855; MCULE-4217888990; NSC 758412; NSC-758412; SDCCGSBI-0050831.P004; IDI1_000693; IDI1_002137; NCGC00015725-01; NCGC00015725-03; NCGC00015725-04; NCGC00015725-05; NCGC00015725-06; NCGC00015725-07; NCGC00015725-08; NCGC00015725-09; NCGC00015725-10; NCGC00015725-11; NCGC00015725-12; NCGC00015725-13; NCGC00015725-15; NCGC00015725-16; NCGC00015725-29; NCGC00021842-03; NCGC00021842-04; NCGC00021842-05; NCGC00021842-06; NCGC00021842-07; NCGC00021842-08; NCGC00255661-01; NCGC00261540-01; AK163559; SBI-0050831.P003; DB-052029; AB00052332; EU-0100855; FT-0630650; N0984; ST51015069; SW196785-3; (methylsulfonyl)(4-nitro-2-phenoxyphenyl)amine; D01049; N 1016; Q20994; AB00052332-16; AB00052332_17; AB00052332_18; n-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide; N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide; 803N782; A828786; SR-01000000218-2; SR-01000000218-6; SR-01000000218-7; W-105866; BRD-K76775527-001-06-2; BRD-K76775527-001-18-7; SR-01000000218-11; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimesulide, European Pharmacopoeia (EP) Reference Standard; Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material; Nimesulide for peak identification, European Pharmacopoeia (EP) Reference Standard; 1364966-82-4
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Colorectal cancer [ICD-11: 2B91] | Terminated | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption
The drug is rapidly absorbed following oral administration
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Elimination
2% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 1.8C4.7 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.2671 micromolar/kg/day
Water Solubility
The ability of drug to dissolve in water is measured as 0.014 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C13H12N2O5S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2
|
|||
| InChI |
1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
|
|||
| InChIKey |
HYWYRSMBCFDLJT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51803-78-2
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Zerumbone | Zingiber zerumbet | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Colitis was induced in female ICR mice at 7 weeks of age. | |||||
| Experimental
Result(s) |
ZER is a novel food factor for mitigating experimental UC and that use of a combination of agents, with different modes of actions, may be an effective anti-inflammatory strategy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Lactotransferrin (LTF) | Molecule Info | [3] | |
| Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [3] | ||
| TNF-related apoptosis-inducing ligand (TRAIL) | Molecule Info | [4] | ||
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Aspirin triggered resolvin D biosynthesis | |||
| 3 | C20 prostanoid biosynthesis | |||
| 4 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Cytokine-cytokine receptor interaction | Click to Show/Hide | ||
| 2 | FoxO signaling pathway | |||
| 3 | Apoptosis | |||
| 4 | Natural killer cell mediated cytotoxicity | |||
| 5 | Measles | |||
| 6 | Influenza A | |||
| 7 | Arachidonic acid metabolism | |||
| 8 | Metabolic pathways | |||
| 9 | NF-kappa B signaling pathway | |||
| 10 | VEGF signaling pathway | |||
| 11 | TNF signaling pathway | |||
| 12 | Retrograde endocannabinoid signaling | |||
| 13 | Serotonergic synapse | |||
| 14 | Ovarian steroidogenesis | |||
| 15 | Oxytocin signaling pathway | |||
| 16 | Regulation of lipolysis in adipocytes | |||
| 17 | Leishmaniasis | |||
| 18 | Pathways in cancer | |||
| 19 | Chemical carcinogenesis | |||
| 20 | MicroRNAs in cancer | |||
| 21 | Small cell lung cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| 2 | IL4 Signaling Pathway | |||
| 3 | TGF_beta_Receptor Signaling Pathway | |||
| 4 | TNFalpha Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | IL1 Signaling Pathway | |||
| 7 | TSH Signaling Pathway | |||
| 8 | IL5 Signaling Pathway | |||
| 9 | TCR Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | Endothelin signaling pathway | |||
| 3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 4 | Toll receptor signaling pathway | |||
| 5 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| Pathway Interaction Database | TRAIL signaling pathway | Click to Show/Hide | ||
| 2 | Caspase Cascade in Apoptosis | |||
| 3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 4 | S1P1 pathway | |||
| 5 | C-MYB transcription factor network | |||
| 6 | Signaling mediated by p38-alpha and p38-beta | |||
| 7 | Calcium signaling in the CD4+ TCR pathway | |||
| Reactome | Ligand-dependent caspase activation | Click to Show/Hide | ||
| 2 | Regulation by c-FLIP | |||
| 3 | RIPK1-mediated regulated necrosis | |||
| 4 | CASP8 activity is inhibited | |||
| 5 | Dimerization of procaspase-8 | |||
| 6 | TRAIL signaling | |||
| 7 | ROS production in response to bacteria | |||
| 8 | Amyloid formation | |||
| WikiPathways | Apoptosis | Click to Show/Hide | ||
| 2 | Extrinsic Pathway for Apoptosis | |||
| 3 | Apoptosis Modulation and Signaling | |||
| 4 | TP53 Network | |||
| 5 | Prostaglandin Synthesis and Regulation | |||
| 6 | Arachidonic acid metabolism | |||
| 7 | Aryl Hydrocarbon Receptor | |||
| 8 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 9 | Spinal Cord Injury | |||
| 10 | Integrated Pancreatic Cancer Pathway | |||
| 11 | Eicosanoid Synthesis | |||
| 12 | Selenium Micronutrient Network | |||
| 13 | Latent infection of Homo sapiens with Mycobacterium tuberculosis | |||
